Skip to main content
OpenTrials
Completed

NCT Number: NCT00874068

The Effects of Dietary Palmitic Acid Triacylglyceride Position on Bone Strength Parameters in Infants

The purpose of this study is to determine the effect of high sn-2 palmitic acid based infant formula on bone strength parameters.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 1 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Meir Medical Center

Kfar Saba, Israel

About this study

InFatTM is an advanced basic-fat ingredient, which mimics the fat composition and properties of human milk fat and enabling optimal intake of the essential calcium and energy (in the form of fatty acids) and easy digestion. These benefits are the results of a unique fatty acid composition on the glycerol backbone, which ensure high level of palmitic acid at the middle (sn-2) position.

The purpose of this study is to determine the effect of high sn-2 palmitic acid based infant formula on bone strength parameters, anthropometric parameters, wellbeing and stool characteristics in term and preterm infants.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gestational age above 32 weeks as determined by menstrual history and corroborated by prenatal US and/or physical examination.
  • Birth weight appropriate for gestational age (AGA) using current CDC growth charts, and above 1750gr.
  • The mother had unequivocally decided not to breast-feed (in formula groups) or the mother had decided to breast feed (in human breast milk group).
  • The infant is apparently healthy.
  • Parental/ legal guardian written inform consent
  • Apgar after 5 minutes >7
  • Enrolled within their first 14 days of life for term infants and first month of life for preterm infants
  • At enrollment: clinical stability and acceptable weight gain

Exclusion criteria

  • The infant suffer from a congenital or chromosomal disorder (Cystic fibrosis, Tracheomalacia, Tracheoesophageal fistula, major congenital heart disease, down-syndrome)
  • The infant suffer from neonatal morbidities:
  • Bronchopulmonary dysplasia (BPD)
  • Intraventricular Hemorrhage3-4 (IVH)
  • Necrotizing Enterocolitis (NEC)
  • Laboratory or clinical sings of Osteopenia
  • The infant suffers from any suspected or known metabolic or physical limitations interfering with feeding or normal metabolism (require a special formula)
  • The mother suffers from any disease or disability that may interfere with her ability to take care of her infant
  • Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study

Treatment and study plan

InFat™ based infant formula

Other

high sn-2 palmitic acid oil based infant formula

Other names: high sn-2 palmitic acid, structured triglyceride

Standard vegetable oil based infant formula

Other

standard vegetable oil based infant formula

Other names: standard vegetable oil

Primary outcomes

  1. bone strength parameters

    Time frame: baseline, 40 corrected gestation weeks, 6 weeks, 12 weeks

Secondary outcomes

  1. stool characteristics

    Time frame: baseline, 40 corrected gestation weeks, 6 weeks, 12 weeks

  2. Antropometric measurements

    Time frame: baseline, 40 corrected gestation weeks, 6 weeks, 12 weeks

Sponsors and collaborators

Lead sponsor

Enzymotec

Industry

Registry information

Official study title

The Effects of Dietary Palmitic Acid Triacylglyceride Position on Anthropometric Measures, Bone Strength Parameters, Stool Characteristics and Stool Biochemistry in Preterm and Term Infants

Acronym: InFat_002

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Apr 2, 2009
Registry last updated
Feb 24, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.